Cargando…

Dawning precision treatment for gastric cancer: The latest biomarkers

Detalles Bibliográficos
Autores principales:	Sun, Keran, Lv, Huifang, Chen, BeiBei, Nie, Caiyun, Zhao, Jing, Wang, Saiqi, Wang, Jianzheng, Xu, Weifeng, Chen, Xiaobing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802398/ https://www.ncbi.nlm.nih.gov/pubmed/35136720 http://dx.doi.org/10.2478/jtim-2021-0023

Ejemplares similares

Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer
por: Lv, Huifang, et al.
Publicado: (2021)

Corrigendum: Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer
por: Lv, Huifang, et al.
Publicado: (2021)

Molecular subtypes based on Wnt-signaling gene expression predict prognosis and tumor microenvironment in hepatocellular carcinoma
por: Xu, Weifeng, et al.
Publicado: (2022)

High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study
por: Nie, Caiyun, et al.
Publicado: (2023)

Tailoring second-line or above therapy for patients with advanced or metastatic gastric cancer: A multicenter real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study
por: Nie, Caiyun, et al.
Publicado: (2022)

Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2021)

Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer
por: Chen, Beibei, et al.
Publicado: (2022)

The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study
por: Nie, Caiyun, et al.
Publicado: (2021)

Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study
por: Nie, Caiyun, et al.
Publicado: (2022)

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
por: Wang, Jianzheng, et al.
Publicado: (2022)

Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model
por: Wang, Jianzheng, et al.
Publicado: (2022)

A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report
por: Wang, Jianzheng, et al.
Publicado: (2021)

DAWN OF PRECISION IN PSYCHIATRY
por: Sethi, B. B.
Publicado: (1981)

Combination of Anlotinib and Celecoxib for the Treatment of Abdominal Desmoid Tumor: A Case Report and Literature Review
por: Wang, Jianzheng, et al.
Publicado: (2022)

Latest therapeutic target for gastric cancer: Anthrax toxin receptor 1
por: Sun, Ke-Ran, et al.
Publicado: (2021)

Retrospective Study on the Efficacy and Safety of Pyrotinib-Based Therapy for HER2-Positive Nonbreast Advanced Solid Tumors
por: Wang, Jianzheng, et al.
Publicado: (2022)

Overview on the Role of E-Cadherin in Gastric Cancer: Dysregulation and Clinical Implications
por: Zhao, Huichen, et al.
Publicado: (2021)

Intranasal esketamine and the dawn of precision psychiatry
por: Watts, Devon, et al.
Publicado: (2021)

Knockdown of Kremen2 Inhibits Tumor Growth and Migration in Gastric Cancer
por: Chen, Beibei, et al.
Publicado: (2021)

MicroRNA-6884-5p Regulates the Proliferation, Invasion, and EMT of Gastric Cancer Cells by Directly Targeting S100A16
por: Lv, Huifang, et al.
Publicado: (2020)

The dawn of precision medicine in diffuse-type gastric cancer
por: Ooki, Akira, et al.
Publicado: (2022)

Adding of apatinib and camrelizumab to overcome de novo trastuzumab resistance of HER2-positive gastric cancer: A case report and literature review
por: Lv, Huifang, et al.
Publicado: (2023)

EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives
por: Sun, Keran, et al.
Publicado: (2020)

The Dawn of Litholapaxy
Publicado: (1900)

The Dawn of Modern Pathology
por: Ferraz de Campos, Fernando Peixoto
Publicado: (2016)

Dawn of Precision Medicine in Psoriatic Arthritis
por: Miyagawa, Ippei, et al.
Publicado: (2022)

A new dawn in ICUrology
por: Park, Kwangsung
Publicado: (2017)

The Dawn of a Health Age
Publicado: (1911)

At the Dawn of Applied DNA Nanotechnology
por: Linko, Veikko
Publicado: (2020)

Hypoxia-inducible factor 1-alpha expression correlates with response to neoadjuvant chemotherapy in women with breast cancer
por: Nie, Caiyun, et al.
Publicado: (2018)

ERAS – The dawn of a new era!
por: Gopinath, Ramachandran, et al.
Publicado: (2019)

Pacific Eclipse: Before the corona dawn
por: Kelleher, Anthony D.
Publicado: (2022)

Dr. Dawn K. Smith, in memoriam
por: Kourtis, Athena P., et al.
Publicado: (2023)

Biomarkers Use and Development in Hepatology: Insights on the Latest Applications
por: Mangia, Alessandra
Publicado: (2022)

The Latest
Publicado: (1902)

A new dawn for critical care research
por: Singer, Mervyn, et al.
Publicado: (2013)

The dawn of a new era in treating T-PLL
por: Schrader, Alexandra, et al.
Publicado: (2019)

Dawn of a new era of diabeto‐oncology
por: Noto, Hiroshi
Publicado: (2020)

The Dawning of the Age of Personalized Medicine in Gynecologic Oncology
por: Leslie, Kimberly K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g121ji46cg290f7qu1u9kob5jn